Axil

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

Since 2026-07-07

ROUNDS

joined, none as lead

ROUNDS JOINED · USD

$67.4M

across 1 round

LATEST ROUND

Series D+ · $67.4M · 2026-07-07

CO-INVESTORS

named beside it

Rounds

[ 1 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours	Series D+ Verified against 1 of 6 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$67.4M	2026-07-07	[ PART ]